Jasper Therapeutics (JSPR)

What Moves the Stock

1. 01JSP191 clinical trial data readouts and patient enrollment milestones in transplant conditioning studies
2. 02FDA regulatory interactions including IND clearances, Fast Track designations, and Breakthrough Therapy status
3. 03Partnership announcements or licensing deals with major pharmaceutical companies for commercialization rights
4. 04Cash runway updates and equity financing announcements given negative $100M operating cash flow
5. 05Competitive developments in CD117-targeting therapies or alternative transplant conditioning approaches
6. 06No current revenue - clinical-stage development company
7. 07Future potential: JSP191 licensing/partnership agreements for transplant conditioning
8. 08Future potential: JSP191 commercial sales for chronic spontaneous urticaria indication

JSPR Chart

My Notes

• growth - Attracts speculative biotech investors and venture-style public market funds willing to accept binary clinical trial risk…
• Rising interest rates create significant headwinds through two mechanisms: (1) higher discount rates compress NPV of future cash flows…
• Watch on earnings: JSP191 Phase 2/3 trial enrollment rates and data readout timelines for transplant conditioning indication, Cash balance and quarterly operating cash burn rate to calculate runway until next financing event, NASDAQ Biotechnology Index (NBI) performance as proxy for sector sentiment and financing window availability.